Prevention of Hypoglycemia Among Diabetes Patients Admitted to Internal Medicine Departments With Nutritional Care
NCT03802942 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 500
Last updated 2021-04-23
Summary
This is a prospective randomized study to evaluate the efficacy of nutritional intervention for the prevention of hypoglycemia among diabetes patients with low albumin level that are admitted to internal medicine units, regardless of the reason for admission. All patients suitable for participation in the study will be asked to participate and be randomized to the interventional arm or the control arm.
After admission to the internal medicine unit, eligible patients will be asked to participate in the study. After signing an informed consent form, patients will be randomized to the treatment or control arms. For patients allocated to the treatment arm, the physician in charge will prescribe 2 portions of GlucernaTM per day as part of the treatment protocol. The nurse in charge of the patient (at either the morning or evening shifts) will make sure the patient is receiving and consuming the ONS.
For every patient included in the interventional arm, 2 bottles of GlucernaTM will be supplied to the patient, one at 08:00 with the morning medications, and one at 16:00 with the evening medications. For clarification purposes, the GlucernaTM will be supplied on top of the designated meal plan, as "over-feeding". Evaluation of adequate ONS consumption will be performed 2-3 hours after the dispensing of the ONS (at 10:00-11:00 and 19:00-21:00), and the amount consumed will be documented.
Patients in the control arm will receive no oral nutritional supplementation, and their caloric intake will be composed of the food supplied by the hospital. Other analysis will be considered usual care. Additional diet consultations as requested by the medical staff will constitute usual care, and the patient will continue the study.
The duration of ONS treatment will be the entire length of hospital stay. Upon discharge, a recommendation to continue nutritional care will be added to the patients' discharge letters but no oral nutritional supplement (ONS) will be prescribed or dispensed.
Following discharge, a 30-day follow-up call will be made to ascertain whether the patient is alive, whether the patient was re-admitted or re-hospitalized, and the usage of ONS prescribed by the family/general practitioner that was consumed after the hospital discharge.
Conditions
- Hypoglycemia
- Malnutrition; Diabetes
Interventions
- DIETARY_SUPPLEMENT
-
Glucerna
1 bottle in the morning with breakfast and 1 bottle in the evening with dinner
Sponsors & Collaborators
-
Abbott Nutrition
collaborator INDUSTRY -
Eyal Leibovitz
lead OTHER
Principal Investigators
-
Eyal Leibovitz, MD · Yoseftal Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-07-01
- Primary Completion
- 2022-12-31
- Completion
- 2023-12-31
Countries
- Israel
Study Locations
More Related Trials
-
The Effect of Hypoglycaemia on Brain Lactate Accumulation and Cerebral Blood Flow
NCT02146404 ·Status: COMPLETED ·Phase: NA
-
Normoglycaemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation (NICE - SUGAR STUDY)
NCT00220987 ·Status: COMPLETED ·Phase: PHASE4
-
Intensive Versus Conventional Hyperglycemic Control in Hospitalized Non-critically Ill Patients
NCT03510078 ·Status: COMPLETED ·Phase: NA
-
Achieving Normal Glucose In Hospital Settings
NCT01359241 ·Status: COMPLETED ·Phase: NA
-
Identification of Inpatients at Risk for Poor Glycemic Control
NCT01043042 ·Status: COMPLETED
-
Blood/Interstitial Glucose Measurements and Cognitive Function During Hypoglycemia and Recovery
NCT01283126 ·Status: COMPLETED ·Phase: NA
-
The Role of Endogenous Lactate in Brain Preservation and Counterregulatory Defenses Against Hypoglycemia
NCT02308293 ·Status: COMPLETED ·Phase: NA
-
Identifying the Brain Substrates of Hypoglycemia Unawareness in Type 1 Diabetes
NCT02866435 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Insulin-based Strategies to Prevent Hypoglycemia During Two Types of Exercise
NCT03845114 ·Status: COMPLETED ·Phase: NA
-
Tight Glycemic Control and Insulin Administration During Parenteral Nutrition
NCT02035943 ·Status: COMPLETED ·Phase: NA
-
Hypoglycemia: Physician and Patient Perspectives
NCT01176656 ·Status: COMPLETED
-
The Effect of Intravenous Lactate on Brain Lactate Concentrations During Hypoglycemia
NCT03286816 ·Status: COMPLETED ·Phase: NA
-
Hypoglycemia and the Mineralocorticoid Receptor
NCT01394627 ·Status: COMPLETED ·Phase: NA
-
Carbohydrate-based Strategies to Prevent Exercise-induced Hypoglycemia
NCT03214107 ·Status: COMPLETED ·Phase: NA
-
Hyperglycemia in Patients with Stroke and Indication of Enteral Nutrition
NCT03422900 ·Status: COMPLETED ·Phase: NA
-
Glycemic Index Variation During Low-carbohydrate Enteral Formula With and Without Fructose in Critically Ill Patients
NCT03003507 ·Status: COMPLETED ·Phase: PHASE4
-
Hypoglycemia (Low Blood Sugar) and the Heart
NCT01980914 ·Status: COMPLETED ·Phase: NA
-
Liver Glycogen and Hypoglycemia in Humans
NCT03241706 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Preventing Hypoglycemia
NCT01923688 ·Status: COMPLETED ·Phase: NA
-
Comparison of Two Insulin Regimens in Optimally-controlled Patients With DM2.
NCT01627509 ·Status: UNKNOWN
-
Hypoglycemia and Autonomic Nervous System Function-B
NCT03429946 ·Status: COMPLETED ·Phase: PHASE4
-
Sulfonylurea Effects on Glucagon Regulation During Hypoglycemia in Type 1 DM
NCT00515801 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Hypoglycemia Prevention in High-Risk Type 2 Diabetes Patients
NCT06746714 ·Status: COMPLETED ·Phase: NA
-
Treatment of Hypoglycemia in Type 1 Diabetes
NCT03489967 ·Status: COMPLETED ·Phase: NA
-
Hypoglycemia Requiring Emergency Services Intervention: Patient Characteristics, Outcome and Cardiovascular Risk Profile
NCT04422145 ·Status: COMPLETED ·Phase: NA